42.01

1.87% -0.80

Supernus Pharmaceuticals Inc (SUPN)

Overview News Price History Option Chain Financials Discussions Forecast

Supernus Pharmaceuticals Inc stock is traded at $42.01, with a volume of 1.20M. It is down -1.87% in the last 24 hours and up +0.89% over the past month. Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.

Previous Close:

$42.81

Open:

$42.94

24h Volume:

1.20M

Relative Volume:

1.52

Market Cap:

$2.45B

Revenue:

$776.83M

Net Income/Loss:

$-29.02M

P/E Ratio:

-82.05

EPS:

-0.512

Net Cash Flow:

$82.25M

1W Performance:

-1.91%

1M Performance:

+0.89%

6M Performance:

-15.90%

1Y Performance:

-13.17%

1-Day Range:

$41.71

$43.29

1-Week Range:

$41.13

$43.41

52-Week Range:

$40.51

$59.68

Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile

Name

Supernus Pharmaceuticals Inc

Sector

Healthcare (1051)

Industry

Drug Manufacturers - Specialty & Generic (84)

Phone

301-838-2500

Address

9715 KEY WEST AVENUE, ROCKVILLE, MD

Employee

778

Twitter

@Supernus_Pharma

Next Earnings Date

2026-11-03

Latest SEC Filings

SUPN's Discussions on Twitter

Compare SUPN vs TAK, TEVA, HLN, ZTS, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SUPN Supernus Pharmaceuticals Inc	42.01	2.45B	776.83M	-29.02M	82.25M	-0.512
TAK Takeda Pharmaceutical Co Adr	18.52	59.16B	29.91B	1.30B	3.49B	0.4056
TEVA Teva Pharmaceutical Industries Ltd Adr	41.25	48.11B	17.53B	1.58B	444.18M	1.3457
HLN Haleon Plc Adr	9.44	41.51B	14.54B	2.22B	2.58B	0.4871
ZTS Zoetis Inc	74.30	30.70B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	543.40	23.31B	3.17B	1.29B	1.01B	27.09

Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-09-25	Upgrade	Piper Sandler	Neutral → Overweight
Jul-30-25	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Feb-19-25	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Jan-06-25	Initiated	Cantor Fitzgerald	Overweight
Sep-11-24	Downgrade	Piper Sandler	Overweight → Neutral
Jan-03-23	Resumed	Jefferies	Buy
Dec-01-21	Resumed	Jefferies	Buy
Apr-13-21	Upgrade	Jefferies	Hold → Buy
Jun-16-20	Upgrade	Piper Sandler	Neutral → Overweight
Jun-15-20	Resumed	Jefferies	Hold
Nov-08-19	Downgrade	Berenberg	Buy → Hold
Nov-07-19	Downgrade	Stifel	Buy → Hold
Nov-06-19	Downgrade	Jefferies	Buy → Hold
Nov-12-18	Reiterated	B. Riley FBR	Buy
Jan-18-18	Reiterated	B. Riley FBR, Inc.	Buy
Dec-28-17	Reiterated	B. Riley FBR, Inc.	Buy
Dec-04-17	Upgrade	Janney	Neutral → Buy
Nov-08-17	Upgrade	Stifel	Hold → Buy
Oct-19-17	Initiated	FBR & Co.	Buy
Sep-19-17	Downgrade	Stifel	Buy → Hold
Jul-17-17	Downgrade	Piper Jaffray	Overweight → Neutral
Jul-14-17	Initiated	Janney	Neutral
Jun-01-17	Upgrade	Piper Jaffray	Neutral → Overweight
Jul-18-16	Downgrade	Northland Capital	Outperform → Market Perform
Jul-18-16	Downgrade	Piper Jaffray	Overweight → Neutral
Feb-08-16	Upgrade	Jefferies	Hold → Buy
Nov-05-15	Reiterated	Northland Capital	Outperform
Oct-28-15	Initiated	Northland Capital	Outperform

View All

Supernus Pharmaceuticals Inc Stock (SUPN) Latest News

Sep 28, 2026

Is Supernus Pharmaceuticals Inc (SUPN) Overvalued After 4.5% Ral - GuruFocus

Sep 28, 2026

Sep 24, 2026

Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc.SUPN - Business Wire

Sep 24, 2026